Endometrial Cancer

Study: Study: Endometrial cancer risk for people with BRCA1 and BRCA2 mutations

This study looked at how often endometrial cancer occurred in people with BRCA1 or BRCA2 mutations to better understand how BRCA mutations affect the risk of endometrial cancer. The researchers also asked whether known risk factors for endometrial cancer impact the frequency of endometrial cancer in people with BRCA1 or BRCA2 mutations. Findings from the study highlight the importance of shared conversations between patients and providers regarding risk monitoring and preventive options. (posted 10/7/25)

Study: Cancer may occur at earlier ages in later generations of families with Lynch syndrome

In families with Lynch syndrome mutations, cancer may occur at an earlier age with each generation. This study looked at the effect called anticipation in families with MLH1-associated Lynch syndrome. (Posted 10/3/25)

Guideline: Hereditary cancer gene guidelines expand

The National Comprehensive Cancer Network regularly updates guidelines for several types of hereditary cancer. These recommendations often change when new research is published. Recently, the NCCN expanded its guidelines to include information on hereditary prostate and gastric cancers. (Posted 1/6/25)

Este artículo está disponible en español.

Update: News from the FDA: New endometrial cancer approvals

The FDA recently approved three new immunotherapy treatments (Jemperli, Imfinzi and Keytruda) for advanced endometrial cancer. (Posted 11/7/24)

Este artículo está disponible en español.

Study: Use of cannabis for cancer symptom management

Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)

Este artículo está disponible en español.

Study: Managing the side effects of advanced endometrial cancer treatment

Immunotherapy plus targeted therapy is a treatment option for advanced endometrial cancer that has progressed after prior treatment. People who start the two-drug combination are more likely to have a positive experience if they learn about the possible side effects and when they might occur. The most common side effects and how to manage them are discussed in this review. (Posted 9/25/24)

Este artículo está disponible en español.

Topic: Acupressure for cancer symptom relief

Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)

Este artículo está disponible en español.

Topic: The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors

The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)

Este artículo está disponible en español.

Topic: Experts call for early palliative care for cancer patients

People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)

Este artículo está disponible en español.

Study: Genetic testing among people with cancer can find mutations that may affect treatment and prevention

Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)

Este artículo está disponible en español.